Array
(
    [0] => 
    [1] => next-generation-sequencing-extended-solid-tumor-panel
    [2] => 
)

Extended Solid Tumor Panel – NGS

NEXT GENERATION SEQUENCING: EXTENDED SOLID TUMOR PANEL

(ONCOMINE FOCUS ASSAY)

MUTATION TESTED: Various (52) genes involved in solid organ malignancies indicated in the table below

INDICATIONS FOR ORDERING: Lung, colorectal, pancreaticobiliary, prostate and various solid organ malignancies

METHOD USED:  Next Generation Sequencing (NGS) using Oncomine Focus Assay Kit  provided by ThermoFischer Scientific (LifeTechnologies Inc, USA)

SPECIMENS – Type, storage and transport

  • Type:. Formalin fixed paraffin embedded tissue sections (Tissue block) with adequate tumor proportion. Please provide a hematoxylin and eosin stained slide of the corresponding block for confirmation and microdissection of the

  • Transport: Specimens must be received within 48 hours of collection
  • Storage: Whole Blood or Bone Marrow. Separate specimens must be submitted when multiple tests are ordered.
  • Extracted DNA: Separate specimens must be submitted when multiple tests are ordered.
  • Unacceptable samples: Specimens collected in anticoagulants other than EDTA, haemolysed/clotted samples

TEST DESCRIPTION: This is a next generation sequencing based assay to detect mutations in the genes enlisted below. This assay is done using amplicon based sequencing on the Ion Torrent (LifeTechnologies, USA) PGM and/or S5 platform, with a gene panel prepared and provided by ThermoFischer Scientific  (LifeTechnologies, USA)

TURNAROUND TIME: 15 (fifteen) working days from receipt of sample

QUALITY ASSURANCE & COMPETENCY TESTING: Regular internal quality checks and intra-lab comparisons are performed to ensure accurate and precise results. Material Safety Data Sheets (MSDS) may be ordered upon request. Highly trained personnel performing this test undergo regular competency assessments and attend regular conferences and educational programs in order to stay upbeat with the newer advances in the biology and diagnostics of the disease in question.

ACCREDITATION: NABL

Genes included in Oncomine Focus Assay

Hotspot Genes Copy Number Variants Fusion drivers
ABL1, AKT1, AR, BRAF, CDK4, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ERBB4, ESR1, FGFR2, FGFR3, GNA11, GNAQ, HRAS, IDH1, IDH2, JAK1, JAK2, JAK3, KIT, KRAS, MAP2K1, MAP2K2, MET, MTOR, NRAS, PDGFRA, PIK3CA, RAF1, RET, ROS1, SMO ALK, AR, BRAF, CCND1, CDK4, CDK6, EGFR, ERBB2, FGFR1, FGFR2, FGFR3, FGFR4, KIT, KRAS, MET, MYC, MYCN, PDGFRA, PIK3CA ABL1, AKT3, ALK,AXL, BRAF,EGFR,ERBB2, ERG, ETV1,ETV4, ETV5, FGFR1, FGFR2, FGFR3, MET, NTRK1, NTRK2, NTRK3, PDGFRA, PPARG, RAF1, RET, ROS1

 

 

Our Locations
  • Sir Chotu Ram Marg, Sector – 5, Rohini Institutional Area, Rohini, New Delhi, Delhi – 110085, India

    +91-11-47022222 | Fax +91 11 27051037

  • Squadron Leader Mahender Kumar Jain Marg, Block K, Niti Bagh, New Delhi, Delhi 110049

    +91-11-45822222 / +91-11-45822200

All © reserved to Rajiv Gandhi Cancer Institute & Research Centre
Website Designing & SEO by Techmagnate